Cucurbitacins – A Promising Target for Cancer Therapy

Dr. Abdullah A. Alghasham

College of Medicine, Qassim University, Kingdom of Saudi Arabia

Abstract:

During the last decades a large number of cucurbitacins have been isolated from various plant species belonging to other plant families than Cucurbitaceae. Although the roots and the fruits of plant belong to these Cucurbitaceae species are very bitter, they have been used as folk medicines in some countries because of their wide spectrum of pharmacological activities such as anti-inflammation and anticancer effects. In the last ten years, cucurbitacins had been shown to inhibit proliferation and induced apoptosis utilizing a long array of in vitro and in vivo cancer cell models. Several molecular targets for cucurbitacins have been discovered, such as fibrous-actin, signal transducer and activator of transcription (STAT), cyclooxygenase-2, etc. This review aimed at elucidating the natural sources of some cucurbitacin compounds, their chemical structure and derivatives, physical properties, biological activities and mechanism by which they reduce the proliferation human cancer cells. This widens our armaments against a devastating disease that we are failing to face.

Key words: Cucurbitacin, STAT, Janus kinase (JAK), anti-tumor, anti-inflammation, apoptosis.

Correspondence:

Dr. Abdullah Alghasham
College of Medicine
Qassim University, Qassim, Kingdom of Saudi Arabia
Mobile No.: +966505135216
E-mail: ghasham@qumed.edu.sa
Introduction

Cucurbitacins are a class of highly oxidized tetracyclic triterpenoids. They are widely distributed in the plant kingdom, where they act as heterologous chemical phenomones that protect plants from external biological insults. The magnitude of their broad-spectrum pharmacological bioactivities first attracted attention in the 1960s. Natural and semi-synthetic cucurbitacins show promising anticancer activities ranging from antiproliferation, cell cycle arrest to induction of apoptosis. Cancer is responsible for 12% of the world’s mortality. Treatments include surgery, and radio- and/or chemo-therapy. However, chemotherapy suffers limitations of side-effects, toxicity and drug resistance. Also, most established chemotherapy drugs are lacking specificity toward tumor cells. Therefore, there has been a growing interest in the use of herbs as a promising source of more efficient new therapeutic anticancer drugs. In addition, recent trends in the management of cancer development include increasing awareness and chemoprevention that suggest using natural or synthetic chemicals to prevent initiation and promotional events associated with cancer development. Marine and terrestrial plants and animals are the main sources of natural products. They are considered as a fertile ground for finding novel antitumor drugs. Medicinal plants, used in folk medicine worldwide, are studied in ethnobotany and ethno-pharmacology. Up to the present date, more than 40 new cucurbitacins and cucurbitacin-derived compounds have been isolated from the cucurbitaceae family and from other species of the plant Kingdom. The most significant mechanisms with regard to the apoptotic effects of cucurbitacins are their ability to modify mitochondrial transmembrane potential and transcriptional activities via nuclear factors or genes and their capability to activate or inhibit pro- or anti-apoptotic proteins. In general, cucurbitacins are considered to be selective inhibitors of the JAK/STAT pathways; however, other mechanisms may be implicated in their apoptotic effects, including the MAPK pathway (known to be important for cancer cell proliferation and survival), PARP cleavage, expression of active caspase-3, decreased pSTAT3 and JAK3 levels, as well as decreases in various downstream STAT3 targets such as Mcl-1, Bcl-2, Bcl-XL, and cyclin D3, all of which are implicated in apoptosis and the cell cycle control.

Chemicals structure of cucurbitacins:

Structurally, cucurbitacins are characterized by the tetracyclic cucurbitane nucleus skeleton (triterpenes). The basic structure of triterpenes is built from six isoprene units. Triterpenes are accordingly C30-compounds. Cucurbitacins are derivatives of the hypothetical triterpene hydrocarbon cucurbitane named 19-(10→9-β)-abeo-5 alpha-lanostane (also known as 9-β-methyl-19-nor-lanosta-5-ene), with a variety of oxygen substitutions at different positions. According to the characteristics of their structures, cucurbitacins are divided into twelve categories. Of these, cucurbitacin E, cucurbitacin B, cucurbitacin D and cucurbitacin I are the most widely used for in vitro and in vivo tumor inhibition studies. Cucurbitacin glycosides usually have the saccharide linked to carbon atom 2 (2-O-β-glycosides). Cucurbitacins E and B result from the acetylation of cucurbitacin I and D, a feature that increased hydrophobicity and cytotoxicity.

Physical properties and solubility of cucurbitacins:

At room temperature, cucurbitacins are generally crystalline substances. The chemical structure of cucurbitacins reveals their possession of hydrophobic properties, and thus poor water solubility. To date, only a limited number of polymeric micellar systems have shown positive results in tumor targeted delivery of poorly soluble drugs after systemic administration. Polyethylene oxide block micelles are nanoscopic carriers (20 - 100 nm in size) with a hydrophilic shell/hydrophobic core structure that have shown great promise in the solubility and controlled delivery of hydrophobic drugs. Poly (ethylene oxide)-block-poly (ε-caprolactone) (PEO-b-PCL) and poly (ethylene oxide)-block-poly (α-benzyl carboxylate ε-caprolactone) (PEO-b-PBCL) micelles (<90 nm) were engineered by a co-solvent evaporation technique as nanocarriers for the delivery of cucurbitacins I and B (figure
Bioactivity of cucurbitacins:

Most of cucurbitacins have a potent biological activities depending on the target cells such as cytotoxic, anti-tumor properties, hepatoprotective, anti-inflammatory, antimicrobial, anthelmintic, cardiovascular and anti-diabetic effects. Indeed, these activities were investigated for the most widely used cucurbitacins in vivo and in vitro studies.\\(^{22-24}\) For instance; the antioxidant capacities and free-radical scavenging activities of cucurbitacin B/E glucosides have been demonstrated (figure 1.B). These results show the promising potential of cucurbitacin glucosides in preventing human diseases involving free radical and oxidative damage.\\(^{25}\)

Also, some of the cucurbitacins possess anti-inflammation or analgesic effects. Considering their anti-inflammation activities, it has been demonstrated that they involve the inhibition of the expression of tumor necrosis factor alpha (TNFα) in lymphocytes and in macrophages,\\(^{13}\) and interference with the activity of nuclear factor-kappa-B (NF-κB).\\(^{26-28}\) Also, cucurbitacins are able to inhibit the activity of cyclooxygenases 2 (COX2)\\(^{26}\) and inhibit the production of pro-inflammation mediators through inducible nitric oxide synthase (iNOS).\\(^{26, 28}\) Cucurbitacin R (figure 1.I) anti-inflammation activity was proven on several experimental models of pain and inflammation.\\(^{29}\) In addition, clinical trials with two compounds hemslecins A (25-acetoxy-23, 24-dihydrocucurbitacin F) and B (23, 24-dihydrocucurbitacin F), isolated initially from the genus Hemsleya, showed their efficacy against infectious diseases, such as enteritis, bronchitis, acute tonsillitis, and bacillary dysentery.

Triterpenes have been reported to induce cell death. Several different cucurbitacin compounds have been found to exhibit antiproliferative on numerous human cancer cell lines and tumor xenografts, including breast, prostate, lung, uterine cervix, liver, skin, and brain cancers (see Table1).\\(^{3,17,25,30,31}\) Moreover, the effectiveness of cucurbitacins B, D, E, and I, (figure 1.B, D, E. G) has so far been shown in colon (HCT-116), breast (MCF-7), lung (NCI-H460) and brain (SF-268) cancer cell lines, where cucurbitacin B demonstrated more than 80% proliferation inhibitory effect.\\(^{30}\) Likewise, cucurbitacins A, B, E, I and Q (figure 1, A, B, E, G) were antiproliferative on lung cancer cells (A549). Cucurbitacin I (figure 1G) caused reduction of growth in breast and prostate carcinoma cell lines (MDA-MB-231, MDA-MB-468, Panc-1), in vitro, as well as in nude mice xenograft models.\\(^{31, 32}\) Growth inhibition was accompanied by cell cycle arrest and apoptosis in breast cancer cell lines (MCF-7 and MDA-MB-231) treated with cucurbitacins B and E (figure 1. B, E)\\(^{1, 33}\) Also, cucurbitacin glucosides (B and E) (figure 1. B, E) isolated from Citrullus colocynthis have antiproliferative effect on human breast cancer cells, through accumulation of cells in the growth phase II/mitotic phase (G2/M phases) of the cell cycle accompanied with induction of apoptosis. They also modulated the expression of proteins involved in cell-cycle regulation in both of the estrogen-dependent (MCF-7) and estrogen-independent (MDA-MB-231) human breast cancer cell lines.

Cucurbitacin Q (figure 1.H) induces apoptosis more potently in human and murine tumors. Furthermore, in HeLa cells, cucurbitacins inhibited DNA, RNA, and protein synthesis.\\(^{34}\) Another two cucurbitacins compounds, isolated from the roots of Cayaponia tayuya and identified as 23, 24-dihydrocucurbitacin B and cucurbitacin R, inhibit proliferation and/or induce apoptosis in colon cancer cell lines.\\(^{13, 23}\) Although
cucurbitacin E (Figure 1.E) was capable of inducing and maintaining high proliferation rates in lymphocytes, it inhibited the proliferation of prostate cancer cells and caused disruption of the cytoskeleton structure of actin and vimentin. Moreover, cucurbitacins also inhibited proliferation of normal mitogen-induced T-lymphocytes and endothelial cells accompanied by a disruption of the F-actin and tubulin microfilaments cytoskeleton and reduced cell motility. The latter effects suggest an anti-angiogenesis and anti-metastasis role for cucurbitacins. Both of cucurbitacin E glucoside and cucurbitacin I glucoside – isolated from Citrullus colocynthis growing in Saudi Arabia - had potent in vitro cytotoxic activity against Hepatoma HepG2 cell line and prolonged the survival time, life span and normalizes the biochemical parameters of mice-bearing tumor of Ehrlich's ascites carcinoma. Growth inhibition and cytotoxic effect of cucurbitacin B (figure 1.B) on breast cancer cell lines SKBR-3 and MCF-7 were attributed to G2/M phase arrest and apoptosis. Cyclin D1, c-Myc, and β-catenin expression levels were reduced. Western blot analysis showed increased PARP cleavage suggesting induced caspase activity and decreased mitogenic Wnt-associated signaling molecules β-catenin, galectin-3, cyclin D1 and c-Myc, and corresponding changes in phosphorylated GSK-3β levels. Cucurbitacin B treatment inhibited translocation to the nucleus of β-catenin and galectin-3. T-cell factor (TCF)/lymphoid enhancer factor (LEF)-dependent transcriptional activity was disrupted in cucurbitacin B treated cells as tested by a TCF reporter luciferase activity assay.

On the other hand, combination of cucurbitacin with standard anticancer drugs produced synergistic effects. The combination of cucurbitacin E with doxorubicin resulted in effective cytotoxicity for tumor cells in culture and in vivo, and in decreased tumor size and tumor weight. Moreover, in comparison with single agent treatment, the combination of cucurbitacin B with docetaxel on Hep-2, a human laryngeal cancer cell line produced a greater efficacy in growth inhibition, cell cycle arrest at G2/M phases, and apoptosis induction in vitro, and synergistically inhibition of tumor growth in vivo. A total of six cucurbitacins promoted TRAIL-induced apoptosis (B, I, E, C, D, and K), whereas P was inactive. They sensitized renal adenocarcinoma cells to anticancer effects of TRAIL. The synergistic effect was apparent after short exposure and did not require continued presence of cucurbitacin. Active cucurbitacins induced the proapoptotic caspase-8 activation only after subsequent TRAIL addition. Cucurbitacin-sensitized TRAIL-induced cytotoxicity was inhibited by N-acetyl cysteine suggesting a prooxidant mechanism. However, their TRAIL-sensitizing activity is STAT3-independent. Cucurbitacin D inhibited proliferation and induce apoptosis of T-cell leukemia cells correlating NF-kB inhibition and down-regulation of the expression of antiapoptotic proteins Bcl-xL and Bcl-2. Furthermore, cucurbitacin D induced the accumulation of inhibitor of NF-kB (IkB) by inhibition of proteasome activity. Low doses of cucurbitacin D synergistically potentiated the antiproliferative effects of the histone deacetylase inhibitor VPA. Finally, the proapoptotic and proteasome inhibitory activities of cucurbitacin D also were demonstrated using SCID mice in an in vivo study.

Cucurbitacins, STATs and tumorigenesis:

Signal transducers and activators of transcription (STATs) are a family of seven proteins including STAT 1, 2, 3, 4, 5a, 5b, and 6. STAT3 protein is ubiquitously expressed in most tissues. Each has its unique function to transduce extracellular signals and directly modulate transcription. STAT proteins play important role in regulation of immune response, inflammation, proliferation, differentiation, development, cell survival, and apoptosis. STATs are initially present in inactive forms in the cytoplasm. Upon stimulation by a wide variety of receptor-mediated growth factors such as platelet-derived growth factor (PDGF) or epidermal growth factor (EGF) and cytokines such as interleukin-6 (IL-6) or interferon signaling, STATs associate the cell membrane receptors to be activated via phosphorylation at conserved tyrosine 705 residues either directly by receptor tyrosine kinases, or indirectly by non-receptor tyrosine kinases, e.g., Janus kinases (JAKs) and Src oncogenic kinase. The JAKs then phosphorylation of tyrosine 705 induces STAT dimerization,
nuclear translocation, and DNA binding at STAT-specific sequence in the promoter regions of their target genes to stimulate their transcription. Additionally, serine at the 727 residue in the same domain must also be phosphorylated for complete transcriptional activity. In normal physiological conditions, the activation duration of STAT protein especially STAT3 is temporary and strictly controlled. Figure (2) illustrates the JAK/STAT pathway for activation and inhibition.

STAT3 regulates the expression of genes that mediate proliferation (e.g., c-myc and cyclin D1), suppress proapoptotic genes (e.g., Bcl-xL, Bcl-2 and survivin), and promote angiogenesis through vascular endothelial growth factor (VEGF). Conversely, cytokines can inhibit STAT3 signaling. Cytokine inducible genes constituting the suppressors of cytokine signaling (SOCS) protein family can bind to and inhibit JAKs, thus repressing STAT3 activation. Recently, it is commonly accepted that STAT3 can also be activated by many other cytokines, such as IL-7, IL-10, IL-20, leptin, granulocyte colony-stimulating factor, and epidermal growth factor. Of the seven human STAT genes, STAT3, a common oncogenic signaling pathway, is constitutively activated in many types of cancers, including 82% of prostate cancers, 70% of breast cancers, more than 82% of the carcinomas of the head and neck, 71% of nasopharyngeal carcinoma, over 50% lung cancers and 50% of HCC, leukemias, lymphomas, and multiple myelomas. Unregulated activation of STAT3 was demonstrated in a variety of tumor types, including breast carcinoma, prostate cancer, melanoma, multiple myeloma, and leukemia among others. Various genetic mutations can lead to constitutive activation of STAT3, e.g., over-expression and constitutive activation of epidermal growth factor receptor (EGFR). STAT3 can contribute to tumor growth by initiating the cell cycle, preventing apoptosis, and up-regulating oncopgenes such as c-Myc and Bcl-xL. Furthermore, STAT3 has recently been demonstrated to augment prostate cancer metastasis by promoting prostate cancer cell migration.

Accumulating evidence shows that blocking aberrant activation of STAT3 in tumor results in the inhibition of cancer cell growth, induction of apoptosis and enhancement of anti-cancer immune responses. Cucurbitacins are recognized as anti-tumour agents involving - among other mechanisms - interference with STAT3 signaling, and they also affect the integrity of the actin cytoskeleton. For example, cucurbitacin E inhibits the proliferation of prostate cancer cells and causes disruption of the cytoskeleton structure of actin and vimentin. However, the more potent cucurbitacins A, B, E, I and Q inhibit the phosphorylation of STAT3 and/or JAK2 and thereby preventing STAT3 DNA binding and STAT3-mediated gene transcription in lung cancer A549 cell line. Likewise, cucurbitacin I caused reduction of phospho-STAT3 in breast, prostate and pancreatic carcinoma cell lines (MDA-MB-231, MDA-MB-468 and Panc-1). Surprisingly, cucurbitacins B and E have been shown to induce phosphorylation of STAT3 in breast cancer cell lines (MDA-MB-231 and MCF-7) while still exhibiting growth inhibition. Cucurbitacins I, Q and B inhibited phosphorylation of STAT3 and induce apoptosis in v-Src-transformed NIH3T3 cells, but had limited biological activity in cells with no activated STAT3. This study led to the conclusion that such cucurbitacins exert anti-tumorigenic activity selectively in cells with activated STAT3.

In structure-activity relationship studies with five cucurbitacins; A, B, E, I, and Q, showed that Q inhibited the activation of STAT3 but not JAK2; A inhibited JAK2 but not STAT3 activation; and B, E, and I, inhibited the activation of both. Furthermore, these studies demonstrated that conversion of the C3 carbonyl of the cucurbitacins to a hydroxyl results in loss of anti-JAK2 activity, whereas addition of a hydroxyl group to C11 of the cucurbitacin I caused reduction of phosphorylation of STAT3 and induced apoptosis in v-Src-transformed NIH3T3 cells, but had limited biological activity in cells with no activated STAT3. This study led to the conclusion that such cucurbitacins exert anti-tumorigenic activity selectively in cells with activated STAT3.
JAK2 inhibition is not sufficient to inhibit tumor growth and suggesting that the ability of cucurbitacin Q to inhibit tumor growth is related to its anti-STAT3 activity. These studies further validate STAT3 as a drug discovery target and provide evidence that pharmacological agents - such as cucurbitacin Q - that can selectively reduce the P-STAT3 levels in human cancer cells result in tumor apoptosis and growth inhibition. (31) Although activation of STAT3 has been demonstrated in primary colon tumors, the majority of established colon cancer cell lines lack constitutively activated STAT3. (77, 78) In contrast, K-Ras mutations are found in 30 - 50% of primary colorectal cancers as well as in established colon cancer cell lines. (79) Thus, the presence of oncogenic K-Ras significantly decreased the sensitivity of cells to dihydrocucurbitacin B, cucurbitacin R and cucurbitacin I (13) possibly through K-Ras antagonism with STAT3 activation. Moreover, p53 and p21 protect cells from apoptosis induced by cucurbitacins. Other study confirmed that sensitivity of human colon cancer cell lines to these three cucurbitacins depends on the extent of oncogenic K-Ras and p53/p21 status, and established that cucurbitacins can exert antitumorogenic activity in the absence of activated STAT3.

Conclusion:
Cucurbitacin structures are characterized by the tetracyclic cucurbitane nucleus (triterpenes) with a variety of oxygen substitutions at different positions. Because of the possession of hydrophobic properties and poorly soluble water, polymeric micellar systems exhibited improved antitumor efficacy because of a better solubilization and targeting after local and/or systemic administration. Different cucurbitacin compounds exhibit antitumor proliferation inhibition and induce apoptosis alone or synergistically with other proven anticancer chemicals and cytokines - using numerous human cancer cell lines and tumor xenografts of leukemia, lymphoma, breast, prostate, lung, uterine cervix, liver, skin, colon, laryngeal, brain and pancreatic cancers. In a structure-function related manner, cucurbitacin’s inhibition of phosphorylation of STAT3 and/or JAK2 and their subsequent activation seemed as the major mechanism of their action. Cucurbitacins deserve future investigations targeting their discovery in uninvestigated sources and their derivatives for improving their anticancer abilities. Moreover, preclinical and clinical studies using combined treatment composed of cucurbitacins and standard chem-, immuno- and/or radio-therapies should be planned for.

Table (1): Cucurbitacin compounds from different plant species and their bioactivity on cancer cells.

<table>
<thead>
<tr>
<th>Cucurbitacin</th>
<th>Plant Source</th>
<th>Effectiveness on cancer cell lines</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cucurbitacin A</td>
<td><em>Trichosanthes cucumerina.</em></td>
<td>Lung: A549 cell lines</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>(Snake gourd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Cucurbita andreana.</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Buttercup squash).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Wilbrandia ebracteata.</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(no common name)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Luffa operculata.</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Sponge Cucumber)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cucurbitacinglucosides</td>
<td><em>Citrullus colocynthis.</em></td>
<td>Breast: ER MCF-7 and ER MDA-MB231</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>(Bitter cucumber)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cucurbitacin E &amp; its glucoside (Elaterin)</td>
<td><em>Bacopa monnieri</em></td>
<td>Ovarian sarcoma: M5076. Colon: HCT-116.</td>
<td>30, 32, 37, 42</td>
</tr>
<tr>
<td><strong>Cucurbita andreana</strong> <em>(Winter Squash)</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatocellular: HepG2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Cucurbitacin D** *(Elatericin A)* | **Trichosanthes kirilowii** *(Chinese Cucumber)* | **Cucurbita andreana** *(Winter Squash)* | Hepatocellular: Hep-2. |
| | Lung and lymphoma: HL60, U937, THP, BALL1, Reh, RCH, LY4, Daudi, MD901, SP49, Jeko1 and NCEB1. | Breast: MCF-7. |

| **Dihydrocucurbitacin B** | **Wilbraandia ebracteata** *(no common name)* | **Trichosanthes kirilowii** *(Chinese Cucumber)* | **Cayaponia tayuya** *(Tayuya)* | Leukemia. |
| | Lung and lymphoma: HL60, U937, THP, BALL1, Reh, RCH, LY4, Daudi, MD901, SP49, Jeko1 and NCEB1. | Breast: MCF-7. |

| **Cucurbitacin I &its glucoside** *(Elatericin B)* *(JSI 124)* | **Momordica balsamina L** *(Balsam pear)* | **Cayaponia tayuya** *(Tayuya)* |
| | **Cucurbita andreana** *(Winter Squash)* | **Citrullus colocynthis.** *(Bitter cucumber)* |

| **Cucurbitacin Q** | **Cayaponia tayuya.** *(Tayuya)* | Lung: A549. |
| | Human and murine cancers: A549, MDA-MB-435, and v-Src/NIH 3T3. |  |

| **Cucurbitacin R** | **Cayaponia tayuya.** *(Tayuya)* | Colon: HCT116 and Hke-3. |
Figure (1): The chemical structure of major cucurbitacins
Cucurbitacins – A Promising Target for Cancer Therapy

Figure (2): Mechanism of activation and inhibition of Janus kinases and signal transducer and activator transcription (JAK/STAT) pathway. Upon activator cytokine binding to its receptor on cell surface (e.g., IL-6 receptor), JAK/STAT pathway is activated (left) leading to sequential cell response. Inhibition of signaling process (right) is induced by a particularly inhibitory cytokine, JAK degradation through ubiquitin-proteasome system (Ub), dephosphorylation by cytoplasmic PTP1B or nuclear phosphatase (NPTP), or by inhibition the dimerization of STAT (adapted with modification from Escandell et al., 2008).
References


38. Dakeng S, Duangmano S, Jiratchariyakul W, U-Pratya Y, Bögler O, Patmasiriwat P. Inhibition of Wnt signaling by cucurbitacin


